Kyowa Kirin (4151) Stock Overview
Engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
4151 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Kyowa Kirin Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,698.00 |
| 52 Week High | JP¥2,912.00 |
| 52 Week Low | JP¥2,034.00 |
| Beta | 0.061 |
| 1 Month Change | -3.90% |
| 3 Month Change | 6.77% |
| 1 Year Change | 26.70% |
| 3 Year Change | -7.70% |
| 5 Year Change | -16.98% |
| Change since IPO | 104.39% |
Recent News & Updates
Recent updates
Kyowa Kirin Co., Ltd. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 11
Kyowa Kirin Co., Ltd. Just Beat EPS By 7.6%: Here's What Analysts Think Will Happen Next
Nov 02Kyowa Kirin's (TSE:4151) Dividend Will Be ¥30.00
Sep 30Kyowa Kirin (TSE:4151) Has Announced A Dividend Of ¥30.00
Sep 16Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥30.00
Sep 02Kyowa Kirin Co., Ltd. Just Missed EPS By 39%: Here's What Analysts Think Will Happen Next
Aug 03Kyowa Kirin (TSE:4151) Has Announced That It Will Be Increasing Its Dividend To ¥30.00
Jun 16Kyowa Kirin's (TSE:4151) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 02Kyowa Kirin (TSE:4151) Will Pay A Larger Dividend Than Last Year At ¥30.00
May 15Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 55% And Analysts Are Revising Their Forecasts
May 03Kyowa Kirin (TSE:4151) Is Increasing Its Dividend To ¥30.00
Apr 11Shareholder Returns
| 4151 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 10.5% | 1.7% | -1.7% |
| 1Y | 26.7% | 23.8% | 30.7% |
Return vs Industry: 4151 exceeded the JP Pharmaceuticals industry which returned 23.8% over the past year.
Return vs Market: 4151 underperformed the JP Market which returned 30.7% over the past year.
Price Volatility
| 4151 volatility | |
|---|---|
| 4151 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in JP Market | 9.4% |
| 10% least volatile stocks in JP Market | 2.4% |
Stable Share Price: 4151's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4151's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,161 | Masashi Miyamoto | www.kyowakirin.com |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia.
Kyowa Kirin Co., Ltd. Fundamentals Summary
| 4151 fundamental statistics | |
|---|---|
| Market cap | JP¥1.35t |
| Earnings (TTM) | JP¥67.04b |
| Revenue (TTM) | JP¥496.83b |
Is 4151 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4151 income statement (TTM) | |
|---|---|
| Revenue | JP¥496.83b |
| Cost of Revenue | JP¥127.93b |
| Gross Profit | JP¥368.89b |
| Other Expenses | JP¥301.85b |
| Earnings | JP¥67.04b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 128.06 |
| Gross Margin | 74.25% |
| Net Profit Margin | 13.49% |
| Debt/Equity Ratio | 0% |
How did 4151 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 07:34 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kyowa Kirin Co., Ltd. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |